Posted by Michael Wonder on 12 May 2025
Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near zero global warming potential
11 May 2025 - Trixeo Aerosphere, AstraZeneca’s fixed-dosed triple-combination therapy for COPD, is the Company’s first medicine to transition to the next-generation propellant.
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate), already licensed for the treatment of chronic obstructive pulmonary disease in adults, has now been approved for use in the UK with an innovative, next-generation propellant with near-zero global warming potential.
